Clinical trials
Systemic Lupus Erthematosus clinical trials
Below are recruiting systemic lupus erthematosus clinical trials, each written for real people, not researchers. We’re tracking 18 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07564596RecruitingPhase 1/Phase 2
A Study of Budoprutug for Systemic Lupus Erythematosus
This trial tests budoprutug, an experimental drug, to see if it helps people with systemic lupus erythematosus (SLE) whose disease is not well controlled by current treatments. The drug targets immune cells that may be driving the disease.
Mianyang, SichuanAges 18–65 - NCT07136389RecruitingPhase 1
Testing 2 drugs for active lupus skin disease
This trial tests two new drugs, BCD-256-1 and divozilimab, for people with systemic lupus erythematosus (SLE) who have active skin symptoms not controlled by current treatments. The goal is to see if they are safe and how the body processes them.
Saint PetersburgAges 18–70 - NCT07713940Recruiting
Anti-inflammatory diet study for lupus patients
This study tests whether an anti-inflammatory diet can help people with lupus who are on certain medications. It focuses on reducing pain and improving quality of life over 12 weeks.
La Jolla, CaliforniaAges 18 years+ - NCT06642870Recruiting
Self-management programme for rare rheumatic conditions
This trial is developing a self-management programme for people with rare rheumatic conditions like lupus, vasculitis, myositis, or Sjogren syndrome. It aims to help participants better manage their condition and improve their quality of life.
BristolAges 18 years+ - NCT06737380RecruitingPhase 1
Stem Cell Therapy Study for Active Lupus
This study tests whether a special type of stem cell treatment (called UC-MSC) can help calm lupus when standard medicines aren't enough. It's for people with active lupus who have tried other non-steroid medications.
Charleston, South CarolinaAges 18–75 - NCT06828042RecruitingPhase 1/Phase 2
CAR-γδT cells for refractory autoimmune diseases
This trial tests a new type of immune cell therapy (CAR-γδT cells) that targets a protein called CD19 on your own B cells. It is for people with certain autoimmune diseases that have not gotten better with standard treatments. The goal is to see if this therapy can safely control the disease.
BeijingAges 18–80 - NCT07150000Recruiting
Rheumatic disease research study for patients and healthy volunteers
This study is for people with certain rheumatic conditions (like arthritis, lupus, or vasculitis) and for healthy volunteers. It aims to learn more about these diseases and improve how they are treated.
Bonn, North Rhine-WestphaliaAges 18 years+ - NCT07225543RecruitingPhase 2
Study of 2-HOBA for women with lupus
This trial tests whether a natural compound called 2-HOBA can help women with lupus who also have mildly high blood pressure. It aims to improve blood vessel health and reduce inflammation.
Nashville, TennesseeAges 18 years+ - NCT07278609Recruiting
Safer medication use for older adults with rheumatic conditions
This study tests a program to help doctors choose safer medications for people aged 60 and older who have arthritis or other rheumatic conditions. It aims to reduce the use of potentially harmful drugs and improve overall medication safety.
Montreal, QuebecAges 60 years+ - NCT07348055RecruitingPhase 1/Phase 2
A study of GR1803 for lupus
This trial tests a new drug called GR1803 for people with systemic lupus erythematosus (SLE), an autoimmune disease that causes inflammation. It may help reduce disease activity when standard treatments haven't worked well enough.
Wuhan, HubeiAges 18–60 - NCT07491900RecruitingPhase 1
Study of HB2198 for lupus with moderate to severe symptoms
This trial tests a new drug called HB2198 to see if it can help people with moderate to severe lupus. It may be an option for those whose current treatments haven't worked well enough.
BrisbaneAges 18–65 - NCT07188285Enrolling by invitation
Immune system study for active autoimmune diseases
This study uses a blood test called mass spectrometry to look at the immune system in people with active autoimmune diseases. It aims to find patterns that could help doctors better understand and treat these conditions.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07305116RecruitingPhase 1
CAR T-cell therapy for autoimmune diseases
This trial tests a new immune therapy called CAR T-cells that target two proteins (CD19 and BCMA) to treat autoimmune diseases like lupus, nephrotic syndrome, and others. It is for people whose standard treatments have not worked well enough.
Hangzhou, ZhejiangAges 3 years+ - NCT07507201RecruitingEarly Phase 1
Car-T cells for autoimmune diseases like lupus
This trial tests whether specially-engineered immune cells (CAR-T cells) can help people with certain autoimmune diseases that haven't gotten better with standard treatments. The cells are designed to target and remove faulty B cells that are causing the immune system to attack the body.
Hangzhou, ZhejiangAges 3 years+ - NCT07586267RecruitingEarly Phase 1
CAR-T cell therapy for autoimmune blood diseases
This early-stage trial tests a new type of cell therapy (CAR-T cells) designed to treat severe autoimmune diseases where the immune system attacks the body's own organs. The therapy targets specific immune cells (B cells) that may be causing the disease. It may help patients who haven't improved with standard treatments or can't tolerate them.
Hangzhou, ZhejiangAges 3 years+ - NCT06599658RecruitingPhase 2
COVID-19 booster and flu vaccine timing for people with weak immune systems
This study tests the best timing for a COVID-19 booster and flu shot in people with weakened immune systems, such as organ transplant recipients, people living with HIV, or those with certain autoimmune conditions. It aims to help patients get better protection from both vaccines.
Montreal, QuebecAges 18 years+ - NCT06792799RecruitingEarly Phase 1
CAR-NK cells for B-cell autoimmune diseases
This early phase trial tests a new treatment made from immune cells (CAR-NK cells) that target and destroy overactive B cells. It may help people with lupus, certain kidney diseases, or nephrotic syndrome that hasn't responded to standard therapies.
Hangzhou, ZhejiangAges 3 years+ - NCT07086989Recruiting
Heart health study for kids with chronic conditions
This study looks at heart disease risk in children and young adults (ages 6-25) with long-term health conditions like certain heart, kidney, or diabetes disorders. The goal is to better understand and manage heart risks early.
BudapestAges 6–25
Hear when a new Systemic Lupus Erthematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for systemic lupus erthematosus?
- Yes. Clin2 currently lists 18 recruiting systemic lupus erthematosus studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a systemic lupus erthematosus trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a systemic lupus erthematosus trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.